A method for detecting poly I-cell content using high performance liquid chromatography

Direct detection of polymyocytes in the vaccine by high performance liquid chromatography, using weak anion exchange column and gradient elution technology, the specificity and time-consuming problems of existing phosphorus detection methods are solved, and the rapid and accurate polymyocytes are achieved Testing, suitable for PIC content analysis of vaccines and drugs.

CN117517551BActive Publication Date: 2024-11-05CHENGDU MAXVAX BIOTECHNOLOGY LLC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202311466224.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-03
Publication Date
2024-11-05
Estimated Expiration
2043-11-03

AI Technical Summary

Technical Problem

The existing phosphorus detection methods are poor in detecting polymyocyte content in finished vaccine products, which are susceptible to other components or buffers, resulting in inaccurate detection, and require a long time to hydrolysis process and inconvenient operation.

Method used

Using high performance liquid chromatography, a mixture of phosphate buffer with a mobile phase of 20-50mM and a 0.5-1M sodium chloride solution was used to directly detect the sample through gradient elution and UV detector without requiring a The flow rate and column temperature of the mobile phase are controlled at 0.5-1.5 ml/min and 25-40°C to improve the accuracy and efficiency of the detection.

Benefits of technology

It realizes rapid and accurate detection of polymyocytes, which is simple and easy to perform, has strong specificity and short time consuming, reduces interference to samples, and meets the accurate quantitative analysis needs of PICs in vaccines and drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117517551B_ABST
    Figure CN117517551B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for detecting poly I-cell content by high performance liquid chromatography, and relates to the technical field of liquid chromatography. A weak anion exchange column is used as a chromatographic column, and the mobile phase is: phase A is a 20-50mM phosphate buffer; phase B is a mixed solution of 20-50mM phosphate buffer and 0.5-1M sodium chloride solution; and the detector is an ultraviolet detector. Compared with the existing hydrolysis method, the method provided by the present invention does not require hydrolysis of the sample and can be directly sampled for detection. The method is simple and easy, short in time, high in accuracy, strong in specificity, and less subject to interference. The method provided by the present invention can meet the accurate quantitative analysis of PIC in samples such as vaccines and drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of liquid chromatography, in particular to a method for detecting poly I-cell content by adopting high performance liquid chromatography. Background Art

[0002] Polyinosinic-cytidylic acid (PIC) is a synthetic double-stranded RNA polymer. It is a double-stranded polynucleotide chain formed by pairing polyinosinic acid (Poly I) and polycytidylic acid (Poly C). It is a highly effective interferon inducer. Studies have shown that PIC has strong antiviral, anti-tumor and immunomodulatory effects and is the most effective synthetic interferon inducer. Clinical studies have shown that PIC can significantly enhance the immunogenicity of vaccines when used in combination with a variety of vaccines. At present, the PIC determination methods included in the industry standards (Chemical Drug Standard Upgraded to National Standard, Beijing Drug Standard 1996) or national standards (State Drug Administration Single Page Standard (2000)) are all phosphorus detection methods.

[0003] The phosphorus detection method has poor specificity in finished vaccines and is easily affected by other ingredients or buffers in the vaccine, resulting in inaccurate detection. Liu Lisha et al. used two-step hydrolysis and reversed-phase high-performance liquid chromatography to determine PIC and detect the inosine and cytidine content after PIC hydrolysis. This method requires the sample to be hydrolyzed for about 6 hours, which is time-consuming and inconvenient to operate.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] The object of the present invention is to provide a method for detecting the content of poly I-C by high performance liquid chromatography to achieve rapid and accurate detection of poly I-C.

[0006] The present invention is achieved in that:

[0007] In a first aspect, the present invention provides a method for detecting poly I-cell content using high performance liquid chromatography, comprising the following steps:

[0008] A weak anion exchange column is used as a chromatographic column, and the mobile phase is: phase A is a 20-50mM phosphate buffer; phase B is a mixed solution of 20-50mM phosphate buffer and 0.5-1M sodium chloride solution; the detector is an ultraviolet detector;

[0009] The elution method is gradient elution, and the conditions of gradient elution are as follows:

[0010]

[0011] The present invention adopts high performance liquid chromatography to determine the content of PIC. Compared with the existing hydrolysis method, it does not need to hydrolyze the sample and can be directly sampled for detection. The method is simple and easy to implement, short in time, high in accuracy, strong in specificity, and less subject to interference. The method provided by the present invention can meet the requirements of accurate quantitative analysis of PIC in samples such as vaccines and drugs.

[0012] The mobile phase B is a mixture of phosphate buffer and sodium chloride solution, which has a lower background absorption at 254nm than potassium nitrate or sodium citrate. The lower the baseline, the more accurate the detection result. Sodium chloride in phase B is the optimal elution salt.

[0013] Phase A is 20 mM, or 25 mM, or 30 mM, or 35 mM, or 40 mM, or 45 mM, or 50 mM phosphate buffer.

[0014] Phase B is a mixed solution of 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, or 50 mM phosphate buffer and 0.5 M, 0.6 M, 0.7 M, 0.8 M, 0.9 M, or 1 M sodium chloride solution.

[0015] In a preferred embodiment of the present invention, during the gradient elution process, the flow rate of the mobile phase is 0.5-1.5 ml / min; and the column temperature is 25-40°C.

[0016] In a preferred embodiment of the present invention, during the gradient elution process, the flow rate of the mobile phase is 1-1.5 ml / min; and the column temperature is 25-40°C.

[0017] If the flow rate of the mobile phase is 1-1.5 ml / min, the peak width will be narrower. If it is lower than 1 ml / min, the peak width will become wider.

[0018] The column temperature is, for example, 25°C, 27°C, 28°C, 30°C, 32°C, 35°C, 37°C, or 40°C.

[0019] In a preferred embodiment of the present invention, the size of the weak anion exchange column is 4.6×250 mm, and the particle size is 5 μm.

[0020] In a preferred embodiment of the present invention, the detection wavelength of the ultraviolet detector is 254 nm.

[0021] In a preferred embodiment of the present invention, the pH of the phosphate buffer in the mobile phase A is 5-7, and the pH of the phosphate buffer in the mobile phase B is 5-7.

[0022] For example, the pH of the phosphate buffer in mobile phase A is 5, 5.5, 6, 6.5 or 7, and the pH of the phosphate buffer in mobile phase B is 5, 5.5, 6, 6.5 or 7. The phosphate buffer in phase A or phase B is a phosphate buffer prepared by mixing sodium dihydrogen phosphate and disodium hydrogen phosphate in a ratio of 50%.

[0023] In a preferred embodiment of the present invention, phase B is a mixed solution of 20-50 mM phosphate buffer and 0.75-1 M sodium chloride solution. When phase B is a mixed solution of 20-50 mM phosphate buffer and 0.75-1 M sodium chloride solution, it has a technical advantage of high recovery rate.

[0024] In a preferred embodiment of the present invention, the injection volume is 5-10 μl, including but not limited to 5 μl, 6 μl, 7 μl, 8 μl, 9 μl or 10 μl.

[0025] In a preferred embodiment of the present invention, the method comprises:

[0026] The poly I-C standard solution and the sample to be tested are respectively injected into high performance liquid chromatography for analysis; a standard curve is established based on the concentration and peak area of ​​the poly I-C standard solution; and the poly I-C content of the sample to be tested is obtained according to the peak area of ​​the sample to be tested corresponding to the concentration on the standard curve.

[0027] The poly I-C standard solution is a solution of poly I-C dissolved in sodium chloride. In an optional embodiment, poly I-C of different masses can be dissolved in sodium chloride to obtain poly I-C standard solutions of different mass concentrations, and poly I-C standard solutions of different concentration gradients are used to draw a standard curve.

[0028] In a preferred embodiment of the present invention, the sample to be tested is a vaccine containing poly I-1C or a drug containing poly I-1C.

[0029] Drugs containing poly I-cell include but are not limited to drugs used for preventing and / or treating canine viral diseases, oral ulcers, viral keratitis, herpes simplex, chronic viral hepatitis, and tumors.

[0030] In a preferred embodiment of the present invention, the tumor is an epithelial tumor or a blood tumor, wherein the epithelial tumor includes but is not limited to papilloma, gastrointestinal cancer, uterine cancer, ovarian cancer, cervical cancer, lung cancer, adenocarcinoma, breast cancer, adenoma or squamous cell carcinoma.

[0031] The gastrointestinal cancer is selected from the group consisting of esophageal cancer, gallbladder cancer, stomach cancer, liver cancer, pancreatic cancer, bile duct cancer, small intestine cancer, colorectal cancer and anal cancer.

[0032] In an alternative embodiment, the adenocarcinoma includes but is not limited to lung adenocarcinoma, thyroid cancer, salivary gland cancer, or pancreatic cancer.

[0033] In an alternative embodiment, the adenoma includes but is not limited to a cystadenoma, a fibroadenoma, a pleomorphic adenoma or a polypoid adenoma.

[0034] In an alternative embodiment, breast cancer includes but is not limited to breast epithelial cancer;

[0035] Preferably, the breast cancer is ductal carcinoma or lobular carcinoma.

[0036] Breast cancer, preferably stage II to IV and / or poorly differentiated invasive ductal carcinoma, comedo carcinoma, and medullary carcinoma (preferably grade 2).

[0037] Ovarian cancer, serous and mucinous carcinomas (preferably stages Ic to IIIb), granulosa cell tumors, surface epithelial-stromal tumors (adenocarcinomas), cystadenocarcinomas, and endometrioid tumors.

[0038] Uterine cancer, preferably including endometrioid adenocarcinoma (preferably stage I to IIIc).

[0039] Bladder cancer, preferably including transitional cell carcinoma (preferably stage II to IV).

[0040] Lung cancer, preferably includes small cell lung cancer (preferably stage I to IIIb), non-small cell lung cancer (preferably poorly to moderately differentiated squamous and adenocarcinoma) and large cell lung cancer.

[0041] The squamous cell carcinoma is one or more of oral squamous cell carcinoma, pharyngeal squamous cell carcinoma, laryngeal cancer, esophageal squamous cell carcinoma (eg esophageal squamous cell carcinoma), lip squamous cell carcinoma, uterine squamous cell carcinoma, vaginal squamous cell carcinoma and skin squamous cell carcinoma.

[0042] Oral squamous cell carcinoma (OSCC) is also called oral squamous cell carcinoma. Examples of oral squamous cell carcinoma include but are not limited to tongue squamous cell carcinoma.

[0043] In other embodiments, the squamous cell carcinoma may also be squamous cell carcinoma formed by squamous metaplasia in the bronchus, bladder, renal pelvis and other parts.

[0044] The drug is in the form of tablets, pills, powders, suspensions, gels, emulsions, creams, granules, nanoparticles, capsules, suppositories, injections or sprays.

[0045] Vaccines are made from pathogenic microorganisms and / or their metabolites through attenuation, inactivation or genetic engineering methods. Genetic engineering methods include but are not limited to genetic modification (such as gene mutation), modification of pure vaccine molecules, introduction of vaccine genes into microbial vectors, or modification of DNA.

[0046] The vaccine is prepared by attenuation, inactivation or genetic engineering of pathogenic microorganisms and / or their metabolites; the vaccine is selected from attenuated vaccine, inactivated vaccine, subunit vaccine or nucleic acid vaccine.

[0047] In a preferred embodiment of the present invention, the sampling time is 18-30 minutes. The sampling time is set to be longer than the sample peak time (eg, 12 minutes) to avoid incomplete peaks due to different experimental environments.

[0048] In a second aspect, the present invention also provides the use of the above method in detecting the content of poly I-C in vaccines and / or drugs containing poly I-C.

[0049] The present invention has the following beneficial effects:

[0050] The present invention adopts high performance liquid chromatography to determine the content of PIC. Compared with the existing hydrolysis method, it does not need to hydrolyze the sample and can be directly sampled for detection. The method is simple and easy to implement, short in time, high in accuracy, strong in specificity, and less subject to interference. The method provided by the present invention can meet the requirements of accurate quantitative analysis of PIC in samples such as vaccines and drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0052] Figure 1 The HPLC chromatogram of the sample to be tested in Example 1;

[0053] Figure 2 is the HPLC chromatogram of the standard solution of Example 1;

[0054] Figure 3 The standard curve diagram for determining the PIC content in the vaccine provided in Example 1;

[0055] Figure 4 is the chromatogram of negative control sample;

[0056] Figure 5 The chromatogram of desalting with 1M NaCl;

[0057] Figure 6 The chromatogram of the desalting salt is 0.75 M NaCl;

[0058] Figure 7 The chromatogram of the desalting salt is 0.5 M NaCl;

[0059] Figure 8 This is the chromatographic column diagram of the 1M KNO3 eluted salt sample;

[0060] Fig. 9 Chromatogram of the desalted sample eluted with 1M sodium citrate. DETAILED DESCRIPTION

[0061] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0062] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0063] Example 1

[0064] This embodiment provides a method for determining the PIC content in a vaccine, which comprises the following steps:

[0065] The instruments and equipment involved in the method of this embodiment are as follows:

[0066] Waters 2695 / 2489 high performance liquid chromatograph; Ohaus PWN223ZH balance; Mettler-Toledo FE28 pH meter;

[0067] Proteomix WAX-NP5, 4.6×250mm analytical column

[0068] The reagents involved are as follows:

[0069] Sodium dihydrogen phosphate (AR grade), disodium hydrogen phosphate (AR grade), sodium chloride (AR grade), and ultrapure water were used in the experiment.

[0070] (1) Sample processing

[0071] The sample to be tested is a recombinant vaccine product (recombinant protein vaccine provided by Chengdu Maikekang Biotechnology Co., Ltd. (i.e., the herpes zoster vaccine preparation disclosed in patent publication number CN116350770A), which is directly loaded.

[0072] (2) Preparation of poly I-cell standard solution:

[0073] Weigh an appropriate amount of PIC standard (concentration of 0.4 mg / ml) into a suitable volumetric flask, dissolve it to volume with 0.9% sodium chloride solution, and mix well.

[0074] (3) High performance liquid chromatography detection

[0075] Turn on the high performance liquid chromatograph, connect the chromatographic column, and set the detection parameters as follows: mobile phase flow rate: 1.0 ml / min, detection wavelength: 254 nm, column temperature: 30 °C; elution mode: gradient elution.

[0076] The conditions for gradient elution were as follows:

[0077]

[0078] Prepare the elution mobile phase: Phase A: 20 mM phosphate buffer (pH 7.2); Phase B: 20 ​​mM phosphate buffer and 1 M sodium chloride (pH 7.2). Turn on the pump switch. Let the elution mobile phase flush the chromatographic column and UV detector at a flow rate of 1.0 ml / min.

[0079] When the pressure value displayed on the chromatographic workstation has no obvious change, the pre-treated standard solution group and the sample group to be tested are injected into the high performance liquid chromatography for analysis. The sampling time is 30 minutes from the start of the sample injection.

[0080] A linear curve was drawn with the different concentration levels of the standard solution as the X-axis and the peak area as the Y-axis, and the concentration of the sample to be tested was calculated using the curve (the concentration of the sample to be tested was 0.4 mg / ml). The peak time of PIC was about 12.9 min. Figure 1 is the HPLC chromatogram of the sample to be tested. Figure 2 HPLC chromatogram of the standard solution.

[0081] Standard curve reference Figure 3 As shown, the linear equation is Y=8152456.6X-141054.1, the correlation coefficient is 1.000, and the percent intercept is 2.2%.

[0082] Experimental Example 1

[0083] The method provided in Example 1 was tested for precision (or repeatability).

[0084] Take the same batch of test products (i.e., samples to be tested) in Example 1 and prepare six samples in parallel. Perform PIC detection and result calculation according to the experimental process in Example 1, test each sample once, and collect the peak area of ​​PIC.

[0085] The test results show that the RSD of the PIC peak area in the repeatability test is 0.14%, indicating that the method provided in Example 1 has high precision.

[0086] Experimental Example 2

[0087] The method provided in Example 1 was subjected to a linearity test.

[0088] Sodium chloride standard solutions (0.9% sodium chloride solutions) of PIC were prepared respectively, with mass concentrations (i.e. g / 100 ml) of 25%, 62.5%, 100%, 137.5%, and 175%. The standard solutions were tested according to the method of Example 1 above.

[0089] A linear curve was drawn with concentration as the horizontal axis and peak response as the vertical axis, and the correlation coefficient and percent intercept were calculated.

[0090] The test results show that the linear equation is Y=8175974.5X-97615.2, the correlation coefficient is 1.000, and the percent intercept is 1.5%. The results show that the method of Example 1 has good linearity.

[0091] Experimental Example 3

[0092] Accuracy experiment.

[0093] The PIC standard solution used for adding to the recombinant protein vaccine (i.e., the herpes zoster vaccine preparation disclosed in the patent publication number CN116350770A) provided by Chengdu Maikekang Biotechnology Co., Ltd. is precisely prepared. The PIC standard solution is a standard solution with a mass concentration level of 30%, 50% and 70% of the theoretical PIC concentration value, and a 50% concentration of the vaccine sample is precisely added respectively, mixed, and prepared into three concentrations of low, medium and high test solutions.

[0094] PIC detection was performed according to the method of Example 1, and each sample was measured once, and the final concentration of the sample was calculated by substituting the measured amount into the standard curve, and the recovery rate and RSD were calculated by comparing the measured amount with the theoretical concentration. The recovery rate was 93% to 98%, and the RSD of the recovery rate was 2.4%.

[0095]

[0096] Experimental Example 4

[0097] A specificity experiment was performed on the detection method provided in Example 1.

[0098] Inject negative control samples and samples according to the experimental steps of Example 1, Figure 4 The results showed that the protein in the negative control sample had no interference at the PIC peak.

[0099] Experimental Example 5

[0100] Screen the eluting salts in mobile phase B.

[0101] In this experimental example, 1M KNO3, 1M NaCl, and 1M sodium citrate were used as elution salts in phase B, respectively. In addition, phase B also included 20mM phosphate buffer. Phase A was the same as in Example 1, and the elution peak of PIC was observed.

[0102] The chromatograms of KNO3 eluted salt samples and sodium citrate eluted salt samples are shown in Table 1. Figure 8 and Fig. 9 The experimental results show that KNO3 and sodium citrate both have high background absorption at 254nm, while NaCl has the lowest background absorption at 254nm, and the detection result is more accurate, which means that sodium chloride is the optimal elution salt.

[0103] Experimental Example 6

[0104] Optimization of elution salt concentration in the mobile phase.

[0105] In order to investigate the elution effect of different elution salt concentrations, elution salts of 0.5 M, 0.75 M and 1 M NaCl were prepared respectively. Phase B also included phosphate. The elution peak of PIC was observed and detected according to the chromatographic detection method of Example 1.

[0106] Results reference Figure 5-Figure 7 As shown, Figure 5 The chromatogram of 1M NaCl desalting is shown below. Figure 6 The chromatogram of 0.75M NaCl elution salt is shown in Figure 1. Figure 7 The chromatogram of 0.5M NaCl elution salt. The results show that the peak elution time of PIC containing 0.75M NaCl in phase B is about 21min, and the peak elution time of PIC containing 1M NaCl is about 13min. Therefore, 0.75-1M NaCl is the optimal elution salt concentration. At this elution salt concentration, the experimental time can be shortened and the peak elution effect can be improved.

[0107] Experimental Example 7

[0108] This experimental example optimizes the flow rate.

[0109] In this experimental example, the mobile phase flow rates were set at 0.5 ml / min, 1 ml / min and 1.5 ml / min, respectively, and PIC detection was performed according to the chromatographic detection method of Example 1 above.

[0110] The results showed that a flow rate of 0.5 ml / min led to a wider peak width, and when the peak shapes were similar, 1 to 1.5 ml / min was the optimal flow rate.

[0111] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for detecting poly I-cell content using high performance liquid chromatography, characterized in that: It includes the following steps: The sample to be tested is a vaccine containing poly I-cell or a drug containing poly I-cell; a weak anion exchange column is used as a chromatographic column, and the type of the chromatographic column is Proteomix WAX-NP5; Mobile phase: Phase A is 20-50mM phosphate buffer; Phase B is a mixed solution of 20-50mM phosphate buffer and 0.5-1M sodium chloride solution; the detector is a UV detector; the injection volume is 5-10μl; The elution method is gradient elution, and the conditions of the gradient elution are as follows: ; During the gradient elution process, the flow rate of the mobile phase is 0.5-1.5 ml / min; the column temperature is 25-40° C.; and the detection wavelength of the ultraviolet detector is 254 nm.

2. The method according to claim 1, characterized in that The flow rate of the mobile phase is 1-1.5 ml / min.

3. The method according to claim 1, characterized in that The size of the weak anion exchange column is 4.6×250 mm, and the particle size is 5 μm.

4. The method according to claim 1, characterized in that: The pH value of the phosphate buffer in the mobile phase A is 5-7, and the pH value of the phosphate buffer in the mobile phase B is 5-7.

5. The method according to claim 4, characterized in that The phase B is a mixed solution of 20-50 mM phosphate buffer and 0.75-1 M sodium chloride solution.

6. The method according to claim 1, characterized in that The method comprises: The poly I-C standard solution and the sample to be tested are respectively injected into high performance liquid chromatography for analysis; a standard curve is established based on the concentration and peak area of ​​the poly I-C standard solution; and the poly I-C content of the sample to be tested is obtained according to the peak area of ​​the sample to be tested corresponding to the concentration on the standard curve.

7. The method according to claim 6, characterized in that The sampling time is 18-30min.

8. Use of the method according to any one of claims 1 to 7 in detecting the content of poly I-C in vaccines and / or drugs containing poly I-C.

Citation Information

Patent Citations

  • Herpes zoster vaccine preparation and preparation method thereof

    CN116350770A

  • Nucleic acid derivatives and process for preparing them

    CN1030424A

  • Medicinal composition of polyinosinic cell injection and preparation method thereof

    CN104434784A

  • Quantitative detection method of rabies virus inactivated antigen

    CN110274982A

  • Method for detecting purity of rabies vaccine through SEC-HPLC method and application

    CN115684391A